Page 103 - AN-4-3

Advanced Neurology TG100-115 suppresses glioblastoma cell functions

Author contributions doi: 10.1016/j.ctrv.2019.101896

Conceptualization: Hong-Shuo Sun, Zhong-Ping Feng, 7. Fleig A, Chubanov V. TRPM7. In: Nilius B, Flockerzi V,
Wenliang Chen editors. Mammalian Transient Receptor Potential (TRP)
Formal analysis: Yuanyuan Xu, Rahmah Alanazi Cation Channels. Vol. 1. Berlin, Heidelberg: Springer; 2014.
p. 521-546.
Investigation: Yuanyuan Xu, Wenliang Chen
Methodology: Yuanyuan Xu, Wenliang Chen 8. Yee NS, Kazi AA, Li Q, Yang Z, Berg A, Yee RK. Aberrant
Writing–original draft: Yuanyuan Xu, Xinyang Zhang, Erin over-expression of TRPM7 ion channels in pancreatic
Cross, Barbara Gundi cancer: Required for cancer cell invasion and implicated in
Writing–review & editing: Hong-Shuo Sun, Zhong-Ping tumor growth and metastasis. Biol Open. 2015;4(4):507-514.
Feng, James T. Rutka, F. David Horgen, Andrea Fleig doi: 10.1242/bio.20137088
9. Guilbert A, Gautier M, Dhennin-Duthille I, Haren N,
Ethics approval and consent to participate Sevestre H, Ouadid-Ahidouch H. Evidence that TRPM7 is
Not applicable. required for breast cancer cell proliferation. Am J Physiol
Cell Physiol. 2009;297(3):C493-C502.
Consent for publication doi: 10.1152/ajpcell.00624.2008

Not applicable. 10. Kim BJ, Park EJ, Lee JH, Jeon JH, Kim SJ, So I.
Suppression of transient receptor potential melastatin 7
Availability of data channel induces cell death in gastric cancer. Cancer Sci.
The data supporting this study can be accessed by 2008;99(12):2502-2509.
submitting a request to the lead or corresponding author. doi: 10.1111/j.1349-7006.2008.00982.x
References 11. Chen JP, Luan Y, You CX, Chen XH, Luo RC, Li R.
TRPM7 regulates the migration of human nasopharyngeal
1. Wasilewski A, Serventi J, Kamalyan L, Wychowski T, carcinoma cell by mediating Ca(2+) influx. Cell Calcium.
Mohile N. Acute care in glioblastoma: The burden and the 2010;47(5):425-432.
consequences. Neurooncol Pract. 2017;4(4):248-254.
doi: 10.1016/j.ceca.2010.03.003
doi: 10.1093/nop/npw032
12. Chen WL, Barszczyk A, Turlova E, et al. Inhibition of TRPM7
2. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy by carvacrol suppresses glioblastoma cell proliferation,
with concomitant and adjuvant temozolomide versus migration and invasion. Oncotarget. 2015;6(18):16321-
radiotherapy alone on survival in glioblastoma in a 16340.
randomised phase III study: 5-year analysis of the EORTC-
NCIC trial. Lancet Oncol. 2009;10(5):459-466. doi: 10.18632/oncotarget.3872
13. Wong R, Gong H, Alanazi R, et al. Inhibition of TRPM7
doi: 10.1016/S1470-2045(09)70025-7
with waixenicin A reduces glioblastoma cellular functions.
3. Kannan S, Murugan AK, Balasubramanian S, Munirajan AK, Cell Calcium. 2020;92:102307.
Alzahrani AS. Gliomas: Genetic alterations, mechanisms of doi: 10.1016/j.ceca.2020.102307
metastasis, recurrence, drug resistance, and recent trends
in molecular therapeutic options. Biochem Pharmacol. 14. Wong R, Turlova E, Feng ZP, Rutka JT, Sun HS. Activation
2022;201:115090. of TRPM7 by naltriben enhances migration and invasion of
glioblastoma cells. Oncotarget. 2017;8(7):11239-11248.
doi: 10.1016/j.bcp.2022.115090
doi: 10.18632/oncotarget.14496
4. Murugan AK, Alzahrani AS. Isocitrate dehydrogenase
IDH1 and IDH2 mutations in human cancer: Prognostic 15. Majewska E, Szeliga M. AKT/GSK3β signaling in
implications for gliomas. Br J Biomed Sci. 2022;79:10208. glioblastoma. Neurochem Res. 2017;42(3):918-924.
doi: 10.3389/bjbs.2021.10208 doi: 10.1007/s11064-016-2044-4
5. Murugan AK, Kannan S, Alzahrani AS. Immune checkpoint 16. McCubrey JA, Steelman LS, Chappell WH, et al. Roles
expression and therapeutic implications in IDH1- of the Raf/MEK/ERK pathway in cell growth, malignant
mutant and wild-type glioblastomas. Curr Probl Cancer. transformation and drug resistance. Biochim Biophys Acta.
2025;55:101182. 2007;1773(8):1263-1284.
doi: 10.1016/j.currproblcancer.2025.101182 doi: 10.1016/j.bbamcr.2006.10.001
6. Le Rhun E, Preusser M, Roth P, et al. Molecular targeted 17. Chen WL, Turlova E, Sun CL, et al. Xyloketal B suppresses
therapy of glioblastoma. Cancer Treat Rev. 2019;80:101896. glioblastoma cell proliferation and migration in vitro

Volume 4 Issue 3 (2025) 97 doi: 10.36922/AN025110023